Telmisartan inhibits human urological cancer cell growth through early apoptosis

Matsuyama,Masahide; Funao,Kiyoaki; Kuratsukuri,Katsuyuki; Tanaka,Tomoaki; Kawahito,Yutaka; Sano,Hajime; Chargui,Jamel; Touraine,Jean-Louis; Yoshimura,Norio; Yoshimura,Rikio

doi:10.3892/etm_00000046

Telmisartan inhibits human urological cancer cell growth through early apoptosis

Authors:
- Masahide Matsuyama
- Kiyoaki Funao
- Katsuyuki Kuratsukuri
- Tomoaki Tanaka
- Yutaka Kawahito
- Hajime Sano
- Jamel Chargui
- Jean-Louis Touraine
- Norio Yoshimura
- Rikio Yoshimura
View Affiliations

Affiliations: Department of Transplantation and Clinical Immunology, Claude Bernard University of Lyon and Lyon Hospitals, Lyon, France
Published online on: March 1, 2010 https://doi.org/10.3892/etm_00000046
Pages: 301-306

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiotensin II receptor blockers (ARBs) are widely used as hypertensive therapeutic agents. In addition, studies have provided evidence that ARBs have the potential to inhibit the growth of several types of cancer cells. It was reported that telmisartan (a type of ARB) has peroxisome proliferator-activated receptor (PPAR)-γ activation activity. We previously reported that the PPAR-γ ligand induces growth arrest in human urological cancer cells through apoptosis. In this study, we evaluated the effects of telmisartan and other ARBs on cell proliferation in renal cell carcinoma (RCC), bladder cancer (BC), prostate cancer (PC) and testicular cancer (TC) cell lines. The inhibitory effects of telmisartan and other ARBs (candesartan, valsartan, irbesartan and losartan) on the growth of the RCC, BC, PC and TC cell lines was investigated using an MTT assay. Flow cytometry and Hoechst staining were used to determine whether the ARBs induced apoptosis. Telmisartan caused marked growth inhibition in the urological cancer cells in a dose- and time-dependent manner. Urological cancer cells treated with 100 µM telmisartan underwent early apoptosis and DNA fragmentation. However, the other ARBs had no effect on cell proliferation in any of the urological cancer cell lines. Telmisartan may mediate potent anti-proliferative effects in urological cancer cells through PPAR-γ. Thus, telmisartan is a potent target for the prevention and treatment of human urological cancer.

View Figures

View References

1.	Weidner N, Folkman J, Pozza F, Bevilaqua P, Allred EN and Moore DH: Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst. 84:1875–1887. 1992. View Article : Google Scholar : PubMed/NCBI
2.	Lafyatis R, Thompson NL, Remmers EF, Flanders KC, Roche NS and Kim SJ: Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization. J Immunol. 143:1142–1148. 1989.
3.	Kubota T, Koshizuka K, Williamson EA, et al: Ligand for Peroxisome proliferator-activated receptor-γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58:3344–3352. 1998.
4.	Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:507–514. 1998. View Article : Google Scholar : PubMed/NCBI
5.	See S and Stirling AL: Candesartan cilexetil: an angiotensin II receptor blocker. Am J Health Syst Pharm. 57:739–746. 2000.PubMed/NCBI
6.	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
7.	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
8.	Le Noble FA, Hekking JW, van Straaten HW, Slaaf DW and Struyker Boudier HA: Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol. 195:305–306. 1991.PubMed/NCBI
9.	Le Noble FA, Schreurs NH, van Straaten HW, et al: Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioal-lantoic membrane. Am J Physiol. 264:460–465. 1993.PubMed/NCBI
10.	Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 43:993–1002. 2004.
11.	Inoue K, Kawahito Y, Tsubouchi Y, et al: Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun. 287:727–732. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Yoshimura R, Matsuyama M, Segawa Y, et al: Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 104:597–602. 2003. View Article : Google Scholar
13.	Segawa Y, Yoshimura R, Hase T, et al: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate. 51:108–116. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Hase T, Yoshimura R, Mitsuhashi M, et al: Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology. 60:542–547. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Yoshimura R, Matsuyama M, Hase T, et al: The effect of peroxisome proliferator-activated receptor-γ ligand on urological cancer cells. Int J Mol Med. 12:861–865. 2003.
16.	Burnier M: Angiotensin II type 1 receptor blockers. Circulation. 103:904–912. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Dina R and Jafari M: Angiotensin II-receptor antagonists. Am J Health-Syst Pharm. 57:1231–1241. 2000.PubMed/NCBI
18.	Abali H, Güllü IH, Engin H, Haznedaroğlu IC, Erman M and Tekuzman G: Old antihypertensive as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses. 59:344–348. 2002. View Article : Google Scholar : PubMed/NCBI
19.	Fujimoto Y, Sasaki T, Tsuchida A and Chayama K: Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 495:197–200. 2001. View Article : Google Scholar : PubMed/NCBI
20.	Miyajima A, Kosaka T, Asano T, et al: Angiotensin II type 1 antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 62:4176–4179. 2002.PubMed/NCBI
21.	Goldfarb DA, Diz DI, Tubbs RR, Ferrario CM and Novick AC: Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol. 151:208–213. 1994.PubMed/NCBI
22.	Inwang ER, Puddefoot JR, Brown CL, et al: Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer. 75:1279–1283. 1997. View Article : Google Scholar : PubMed/NCBI
23.	Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y and Murai M: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res. 12:2888–2893. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Kosaka T, Miyajima A, Takayama E, et al: Angiotensin II type I receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate. 67:41–49. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Egami K, Murohara T, Shimada T, et al: Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 112:67–75. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Koh WP, Yuan JM, van Den Berg D, Lee HP and Yu MC: Polymorphisms in angiotensin II type 1 receptor and angiotensin I converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis. 26:459–464. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Uemura H, Hasumi H, Kawahara T, et al: Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 10:405–410. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Kawahito Y, Kondo M, Tsubouchi Y, et al: 15-deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 106:189–197. 2000. View Article : Google Scholar : PubMed/NCBI
29.	Tsubouchi Y, Sano H, Kawahito Y, et al: Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun. 270:400–405. 2000.
30.	Dreyer C, Krey G, Keller H, Givel F, Helftenbein G and Wahli W: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 68:879–887. 1992. View Article : Google Scholar : PubMed/NCBI
31.	Kliewer SA, Umesono K, Noonan DJ, Heyman RA and Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358:771–774. 1992. View Article : Google Scholar : PubMed/NCBI
32.	Kliewer SA, Forman BM, Blumberg B, et al: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA. 91:7355–7359. 1994. View Article : Google Scholar : PubMed/NCBI
33.	Chinetti G, Griglio S, Antonucci M, et al: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 273:25573–25580. 1998. View Article : Google Scholar
34.	Altiok S, Xu M and Spiegelman BM: PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 11:1987–1998. 1997. View Article : Google Scholar : PubMed/NCBI
35.	Keelan JA, Sato TA, Marvin KW, Lander J, Gilmour RS and Mitchell MD: 15-Deoxy-delta (12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. Biochem Biophys Res Commun. 262:579–585. 1999. View Article : Google Scholar : PubMed/NCBI